<div id="readability-page-1"><article><div>, /PRNewswire/ -- TransMedics Group, Inc. (&#34;TransMedics&#34;) (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing of a long-term lease for its new global headquarters at Assembly Innovation Park in Somerville, as well as the acquisition of the adjacent land parcel to create an integrated TransMedics campus environment. This strategic expansion reflects the company's commitment to accelerating the next wave of transplant innovations, growth, and the transformation of global organ transplant therapy.<img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="77" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg"/>The new headquarters will support TransMedics' operational expansion, bringing together corporate, research, development, and advanced manufacturing capabilities in a purpose-built, state-of-the-art facility. TransMedics plans to relocate on or before January 2028. The move is expected to significantly enhance the company's ability to attract and retain top talent to fuel scaling the organization globally.&#34;This new global headquarter is a critical milestone for our mid- and long-term growth initiatives. It validates our commitment to creating a world-class environment to attract and retain the best talent to help us execute our vision to transform transplant medicine globally,&#34; said Waleed Hassanein, M.D., President and Chief Executive Officer. &#34;Establishing our new global headquarters at Assembly Innovation Park, places TransMedics at the center of the Greater Boston life sciences ecosystem, in close proximity to leading academic institutions, clinical transplant centers, and a deep pool of scientific, engineering, and operational talent. We are grateful for the collaboration and supportive efforts of Governor Healey, Lieutenant Governor Driscoll, the City of Somerville and their teams.&#34;TransMedics' expansion advances the Healey-Driscoll Administration's strategy to strengthen Massachusetts' leadership in life sciences innovation. Through the Massachusetts Life Sciences Center (MLSC), the Commonwealth proposes a performance-based incentive package designed to support TransMedics' continued growth while creating high-quality jobs for Massachusetts residents. The proposed package includes tax incentives of up to $30,000 per net new, permanent, full-time job created between 2026 and 2031, with a total potential value of up to $18 million tied to the creation of as many as 600 new jobs. In addition, MLSC has proposed complementary workforce development and equipment investments to help ensure TransMedics can scale its operations and talent base in Massachusetts.&#34;Massachusetts is a global leader in life sciences because of the investments we make in lifesaving, innovative companies like TransMedics. Their expansion into Somerville is a powerful example of how cutting-edge medical innovation and economic growth go hand in hand,&#34; said Massachusetts Governor Maura Healey. &#34;By creating more jobs, they're powering the future of our state's economy, and their revolutionary technology is exactly the kind of leadership Massachusetts is known for. We're thrilled to support their expansion and look forward to the work ahead.&#34;&#34;Companies like TransMedics reflect our commitment to growing a strong, competitive life sciences ecosystem in Massachusetts that delivers real impact for patients and communities,&#34; said Massachusetts Lieutenant Governor Kim Driscoll. &#34;By making smart investments that further this important industry, we're helping innovative companies scale in Massachusetts and strengthening our competitive edge while creating good-paying jobs.&#34; The City of Somerville, Mass., also helped catalyze TransMedics' move with a creative funding package, Tax Increment Financing (&#34;TIF&#34;), providing up to $18M in tax relief over ten years while creating a projected $75M in new local tax revenues for the city over the same period. &#34;As a world-leading MedTech company, TransMedics will fit right in here in Somerville with our growing life science hub,&#34; said Somerville Mayor Jake Wilson. &#34;This is a win for transplant patients, the Commonwealth, the company, and Somerville residents. Not only can Somerville offer room for TransMedics to grow their lifesaving services, but the new tax revenues and an influx of good jobs will open doors for our residents and region across a wide range of career paths from manufacturing to research. We look forward to facilitating TransMedics growth, expansion, and a strong community partnership.&#34; BioMed Realty, the largest privately-owned operator of real estate for the life science and technology industries and whose purpose is to deliver mission-critical infrastructure that enables innovators like TransMedics to focus on advancing technology to improve human health, developed Assembly Innovation Park with an exceptional amenity package, large floor plates, and an ability to accommodate robust programming requirements.Bill Kane, BioMed Realty's President, East Coast and U.K. Markets said, &#34;We are proud to welcome TransMedics to Assembly Innovation Park and to support the company as it enters this next phase of growth. The campus was designed to provide flexibility and operational resilience that companies like TransMedics need to accelerate innovation and change lives.&#34;About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.Forward-Looking Statements This press release contains forward-looking statements. These forward-looking statements address various matters, including, among other things, future results and events, including plans to relocate to the new headquarters on or before January 2028, mid- and long-term growth initiatives, its ability to attract and retain top talent to fuel scaling the organization globally and its commitment to accelerating the next wave of transplant innovations, growth, and the transformation of global organ transplant therapy, expectations regarding the creation of new jobs in Massachusetts, and the anticipated availability, amount, timing, and realization of potential benefits from state and local tax incentive programs, as well as related projections regarding local tax revenues. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words &#34;believe,&#34; &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;expect,&#34; &#34;should,&#34; &#34;could,&#34; &#34;target,&#34; &#34;predict,&#34; &#34;seek&#34; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: the fluctuation of our financial results from quarter to quarter; our ability to attract, train, and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreements to which we will remain subject until maturity; our ability to sustain profitability; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; that we have identified a material weakness in our internal control over financial reporting, and that we may identify additional material weaknesses in the future; our dependence on the success of the Organ Care System (&#34;OCS&#34;); our ability to expand access to the OCS through our National OCS Program (&#34;NOP&#34;); our ability to improve the OCS platform, including by developing the next generation of the OCS products or expanding into new indications; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors of benefits offered by the OCS; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States, the European Union, and other select jurisdictions worldwide; our ability to adequately respond to Food and Drug Administration (&#34;FDA&#34;), or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including recently enacted or potential future legislation reforming the U.S. healthcare system, Organ Procurement and Transplantation Network (&#34;OPTN&#34;), or the FDA; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP to reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration (&#34;FAA&#34;) or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products or services infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the impact of any future U.S. government shutdowns; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the &#34;SEC&#34;). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.Media Contact: Nick Corcoran TransMedics 978 552 0901 mediarelations@transmedics.comInvestor Contact: Brian Johnston Laine Morgan 322 895 3222 Investors@transmedics.comSOURCE TransMedics Group, Inc.</div></article></div>

TMDX

TransMedics Group, Inc. has announced the signing of a long-term lease for its new global headquarters at Assembly Innovation Park in Somerville, Massachusetts, along with the acquisition of adjacent land. This expansion aims to enhance the company's operational capabilities and attract top talent. The Massachusetts government is supporting this move with a performance-based incentive package, potentially worth up to $18 million, tied to the creation of 600 new jobs. The new headquarters is expected to be operational by January 2028, further solidifying Massachusetts' position in life sciences innovation.

TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts | TMDX Stock News